Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Loma Linda, California 92350


Purpose:

The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of hypotension in severe septic patients.


Criteria:

Inclusion Criteria: - Severe sepsis patients treated with 96 hour infusion of commercial Drotrecogin Alfa (Activated) - Continue requirement of Vasopressor support after 96 hour commercial infusion Exclusion Criteria: - Patients require extensive surgical procedures within next 3 days - Patients with platelet count below 30,000/mm3 - Patients receiving therapeutic heparin of 15,000 units/day and more - Patients not expected to survive 24 days - Patients contraindicated as to the country specific registration


NCT ID:

NCT00190788


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

Loma Linda, California 92350
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.